Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite

NeuroToxicology

Volumn 32, Issue 4, 2011, Pages 471-477

  Mexas, Lydia M ^a   Florang, Virginia R ^a   Doorn, Jonathan A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Dopamine metabolite; Enzyme inhibition; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

3,4 DIHYDROXYPHENYLACETALDEHYDE; DOPAMINE; NEUROTOXIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL LYSATE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INHIBITION; METABOLITE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN TARGETING; RAT; WESTERN BLOTTING;

3,4-DIHYDROXYPHENYLACETIC ACID; ADRENAL GLANDS; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; KINETICS; LEVODOPA; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 79955679694     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2011.03.013     Document Type: Article

References (49)

1. Andersen J.K. Oxidative stress in neurodegeneration: cause or consequence?. Nat Med 2004, 10(Suppl.):S18-25.
2. Burke W.J. 3,4-Dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson's disease. Curr Drug Targets CNS Neurol Disord 2003, 2:143-148.
3. Burke W.J., Li S.W., Chung H.D., Ruggiero D.A., Kristal B.S., Johnson E.M., et al. Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology 2004, 25:101-115.
4. Burke W.J., Li S.W., Williams E.A., Nonneman R., Zahm D.S. 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis. Brain Res 2003, 989:205-213.
5. Cartier E.A., Parra L.A., Baust T.B., Quiroz M., Salazar G., Faundez V., et al. A biochemical and functional protein complex involving dopamine synthesis and transport into synaptic vesicles. J Biol Chem 2010, 285:1957-1966.
6. Conway K.A., Rochet J.C., Bieganski R.M., Lansbury P.T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001, 294:1346-1349.
7. Datla K.P., Blunt S.B., Dexter D.T. Chronic l-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov Disord 2001, 16:424-434.
8. Elsworth J.D., Roth R.H. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease. Exp Neurol 1997, 144:4-9.
9. Fleming L., Mann J.B., Bean J., Briggle T., Sanchez-Ramos J.R. Parkinson's disease and brain levels of organochlorine pesticides. Ann Neurol 1994, 36:100-103.
10. Goodwill K.E., Sabatier C., Stevens R.C. Crystal structure of tyrosine hydroxylase with bound cofactor analogue and iron at 2.3Å resolution: self-hydroxylation of Phe300 and the pterin-binding site. Biochemistry 1998, 37:13437-13445.
11. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978, 14:633-643.
12. Graham D.G., Tiffany S.M., Bell W.R., Gutknecht W.F. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 1978, 14:644-653.
13. Hastings T.G., Lewis D.A., Zigmond M.J. Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease. Adv Exp Med Biol 1996, 387:97-106.
14. Hegstrand L.R., Simon J.R., Roth R.H. Tyrosine hydroxylase: examination of conditions influencing activity in pheochromocytoma, adrenal medulla and striatum. Biochem Pharmacol 1979, 28:519-523.
15. Helander A., Tottmar O. Reactions of biogenic aldehydes with hemoglobin. Alcohol 1989, 6:71-75.
16. Hirata Y., Adachi K., Kiuchi K. Activation of JNK pathway and induction of apoptosis by manganese in PC12 cells. J Neurochem 1998, 71:1607-1615.
17. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003, 53(Suppl. 3):S26-36. [discussion S36-28].
18. Jimenez C.R.H.L., Qui Y., Burlingame A.L. Current protocols in protein science 1998, John Wiley and Sons, New York.
19. Jinsmaa Y., Florang V.R., Rees J.N., Anderson D.G., Strack S., Doorn J.A. Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate. Chem Res Toxicol 2009, 22:835-841.
20. Keller A., Nesvizhskii A.I., Kolker E., Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002, 74:5383-5392.
21. Kitazawa M., Anantharam V., Kanthasamy A.G. Dieldrin-induced oxidative stress and neurochemical changes contribute to apoptotic cell death in dopaminergic cells. Free Radic Biol Med 2001, 31:1473-1485.
22. Kristal B.S., Conway A.D., Brown A.M., Jain J.C., Ulluci P.A., Li S.W., et al. Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. Free Radic Biol Med 2001, 30:924-931.
23. Kuhn D.M., Arthur R.E., Thomas D.M., Elferink L.A. Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. J Neurochem 1999, 73:1309-1317.
24. Lamensdorf I., Eisenhofer G., Harvey-White J., Hayakawa Y., Kirk K., Kopin I.J. Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde. J Neurosci Res 2000, 60:552-558.
25. Laschinski G., Kittner B., Brautigam M. Inhibition of striatal tyrosine hydroxylase by low concentrations of apomorphine. Naunyn Schmiedebergs Arch Pharmacol 1984, 327:114-118.
26. Laschinski G., Kittner B., Brautigam M. Direct inhibition of tyrosine hydroxylase from PC-12 cells by catechol derivatives. Naunyn Schmiedebergs Arch Pharmacol 1986, 332:346-350.
27. LaVoie M.J., Ostaszewski B.L., Weihofen A., Schlossmacher M.G., Selkoe D.J. Dopamine covalently modifies and functionally inactivates Parkin. Nat Med 2005, 11:1214-1221.
28. Lees A.J., Hardy J., Revesz T. Parkinson's disease. Lancet 2009, 373:2055-2066.
29. Mattammal M.B., Haring J.H., Chung H.D., Raghu G., Strong R. An endogenous dopaminergic neurotoxin: implication for Parkinson's disease. Neurodegeneration 1995, 4:271-281.
30. McGeer E.G., McGeer P.L., Wada J.A. Distribution of tyrosine hydroxylase in human and animal brain. J Neurochem 1971, 18:1647-1658.
31. Meyer M.J., Mosely D.E., Amarnath V., Picklo M.J. Metabolism of 4-hydroxy-trans-2-nonenal by central nervous system mitochondria is dependent on age and NAD+ availability. Chem Res Toxicol 2004, 17:1272-1279.
32. Murer M.G., Dziewczapolski G., Menalled L.B., Garcia M.C., Agid Y., Gershanik O., et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998, 43:561-575.
33. Nagatsu T., Levitt M., Udenfriend S. Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J Biol Chem 1964, 239:2910-2917.
34. Nakashima A., Hayashi N., Kaneko Y.S., Mori K., Sabban E.L., Nagatsu T., et al. Role of N-terminus of tyrosine hydroxylase in the biosynthesis of catecholamines. J Neural Transm 2009, 116:1355-1362.
35. Nesvizhskii A.I., Keller A., Kolker E., Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003, 75:4646-4658.
36. Nilsson G.E., Tottmar O. Biogenic aldehydes in brain: on their preparation and reactions with rat brain tissue. J Neurochem 1987, 48:1566-1572.
37. Oreland L., Gottfries C.G. Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type. Prog Neuropsychopharmacol Biol Psychiatry 1986, 10:533-540.
38. Pittman R.N., Wang S., DiBenedetto A.J., Mills J.C. A system for characterizing cellular and molecular events in programmed neuronal cell death. J Neurosci 1993, 13:3669-3680.
39. Rees J.N., Florang V.R., Anderson D.G., Doorn J.A. Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate. Chem Res Toxicol 2007, 20:1536-1542.
40. Rees J.N., Florang V.R., Eckert L.L., Doorn J.A. Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol. Chem Res Toxicol 2009, 22:1256-1263.
41. Seegal R.F., Brosch K., Bush B., Ritz M., Shain W. Effects of Aroclor 1254 on dopamine and norepinephrine concentrations in pheochromocytoma (PC-12) cells. Neurotoxicology 1989, 10:757-764.
42. Shafer T.J., Atchison W.D. Transmitter, ion channel and receptor properties of pheochromocytoma (PC12) cells: a model for neurotoxicological studies. Neurotoxicology 1991, 12:473-492.
43. Stokes A.H., Hastings T.G., Vrana K.E. Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 1999, 55:659-665.
44. Strack S. Overexpression of the protein phosphatase 2A regulatory subunit Bgamma promotes neuronal differentiation by activating the MAP kinase (MAPK) cascade. J Biol Chem 2002, 277:41525-41532.
45. Tank A.W., Weiner H., Thurman J.A. Enzymology and subcellular localization of aldehyde oxidation in rat liver. Oxidation of 3,4-dihydroxyphenylacetaldehyde derived from dopamine to 3,4-dihydroxyphenylacetic acid. Biochem Pharmacol 1981, 30:3265-3275.
46. Udenfriend S., Zaltzman-Nirenberg P., Nagatsu T. Inhibitors of purified beef adrenal tyrosine hydroxylase. Biochem Pharmacol 1965, 14:837-845.
47. Ungar F., Tabakoff B., Alivisatos S.G. Inhibition of binding of aldehydes of biogenic amines in tissues. Biochem Pharmacol 1973, 22:1905-1913.
48. Xu Y., Stokes A.H., Roskoski R., Vrana K.E. Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J Neurosci Res 1998, 54:691-697.
49. Zhang L., Yu H., Zhao X., Lin X., Tan C., Cao G., et al. Neuroprotective effects of salidroside against beta-amyloid-induced oxidative stress in SH-SY5Y human neuroblastoma cells. Neurochem Int 2010, 57:547-555.